Skip to content

Mar 2017, Volume 24, Issue 2

March’s edition of the EJHP includes an editorial on “Value or cost”, and original articles on: evaluation of a pharmaceutical assessment screening tool; biosimilar infliximab for the management of rheumatoid arthritis; the cost and efficiency of incident reporting in a specialist paediatric NHS hospital and impact on patient safety; ready-to-use parenteral amiodarone; and much more.

The edition also contains a case report on bradycardia associated with pegylated liposomal doxorubicin administration, as well as a postcript on deprescribing in India: will we ever get down to it?. 

×

Deadline extended to July 15th

Problems caused by shortages are serious, threaten patient care and require urgent action.

Help us provide an overview of the scale of the problem, as well as insights into the impact on overall patient care.

Our aim is to investigate the causes of medicine and medical device shortages in the hospital setting,  while also gathering effective solutions and best practices implemented at local, regional, and national levels.

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.